Skip to main content
Clinical Trials/NCT02941861
NCT02941861CompletedNot Applicable

Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery

Ruechuta Molek0 sites67 target enrollmentStarted: August 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
67
Primary Endpoint
Recurrence rate of Liver Carcinoma after surgery

Study Overview

Brief Summary

Objective:

  1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery
  2. To study the related factors affecting recurrence of liver carcinoma after surgery

Detailed Description

Liver carcinoma including 80% Hepatocellular carcinoma (HCC) and 20% Cholangiocarcinoma (CCA) becomes the leading causes of death in East and South-East Asia. Though hepatectomy is the treatment of choice for early stage cancer, the recurrence has been reported as 30%, 62% and 79% in 1st, 3rd and 5th year respectively. Chulabhorn hospital, a cancer institute established in 2011, has been performing a 3-years retrospective study on the influencing factors and its correlation to liver carcinoma after surgery.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •All patients underwent liver resection for Hepatiocellular carcinoma and Cholangiocarcinoma respectively including having pathology results between February 2010 to December
  • •Data was received from Cholabhron Hospital's patient database.

Exclusion Criteria

  • •All patients having no pathology results were not included.
  • •All patients having no show for follow up recording were excluded.

Outcomes

Primary Outcomes

Recurrence rate of Liver Carcinoma after surgery

Time Frame: 3 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Ruechuta Molek
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Ruechuta Molek

Ms Ruechuta Molek (rmolek)

Chulabhorn Hospital

Similar Trials